Glenmark (GLENMARK) | Stock Overview & Key Data
Glenmark Performance Comparison
Stock Range
Today's Range
Low: ₹2,014.00
High: ₹2,065.00
on August 8, 2025
52 Week Range
Low: ₹1,275.50
High: ₹2,284.80
on February 28, 2025
on July 11, 2025
All-Time High: ₹2,284.80 on July 11, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR582.1B
EPS
37.07
P/E Ratio (TTM)
55.65
Forward P/E
48.56
P/B Ratio
6.77
PEG Ratio
48.56
Div. Yield
0.15%
ROE
12.54%
Beta
0.313
Debt to Equity
27.94
Financial Highlights
Profitability
Gross Margin
66.18%
Operating Margin
13.69%
Profit Margin
7.79%
Returns and Earnings
Return on Assets (TTM)
8.14%
Return on Equity (TTM)
12.54%
EBITDA
INR20.9B
Net Income (TTM)
INR10.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR476.12
Quarterly Revenue Growth (YoY)
-16.10%
Quarterly Earnings Growth (YoY)
6.77%
Dividend Information
Last 12-Month Dividend
₹2.50
Current Dividend Yield
0.15%
3-Year Average Dividend Yield
0.38%
3-Year Average Annual Dividend
₹2.50
3-Year Total Dividends
₹7.50
Ex-Dividend Date
September 13, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Glenmark GLENMARK | 582.12B Large-cap | -2.33% | 10.33% | 42.34% | 33.65% | 25.09% | 37.11% | 419.44% | 324.55% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Cipla CIPLA | 1.20T Large-cap | -1.18% | -0.22% | -0.12% | 1.79% | 0.38% | 3.58% | 45.16% | 93.18% |
| Torrent TORNTPHARM | 1.22T Large-cap | -2.85% | 7.55% | 12.16% | 11.91% | 4.52% | 7.03% | 132.03% | 25.86% |
| Mankind Pharma MANKIND | 1.05T Large-cap | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% | 15.49% | 76.92% | 76.92% |
Ownership & Short Interest
Insider Ownership
49.62%
Institutional Ownership
29.03%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
921K
Average 90-Day Volume
2M
Glenmark Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Glenmark would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GLENMARK's 52-week high and low?
- In the last 52 weeks, Glenmark reached a high of ₹2,284.80 (on July 11, 2025) and a low of ₹1,275.50 (on February 28, 2025).
- What is the market cap and P/E ratio for GLENMARK?
- Curious about Glenmark's size and valuation? Its market capitalization stands at 582.12B. When it comes to valuation, the P/E ratio (trailing twelve months) is 55.65, and the forward P/E (looking ahead) is 48.56.
- Does GLENMARK pay dividends? If so, what's the yield?
- Yes, Glenmark is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.15%, and the company has paid an average of ₹2.50 per share annually over the past 3 years.
- Who are Glenmark's main competitors or similar companies to consider before investing?
When looking at Glenmark, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 7.03% 132.03% Mankind Pharma
MANKIND1.05T Healthcare Drug Manufacturers - Specialty & Generic 15.49% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Glenmark Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Glenmark's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.54%, the Debt to Equity ratio from the most recent quarter is 27.94, and its Gross Profit Margin stands at 66.18%.
- What is the recent revenue and earnings growth for GLENMARK?
- Looking at Glenmark's growth, its revenue over the trailing twelve months (TTM) was INR134B. Compared to the same quarter last year (YoY), quarterly revenue grew by -16.10%, and quarterly earnings saw a YoY growth of 6.77%.
- How much of GLENMARK stock is held by insiders and institutions?
- Wondering who owns Glenmark stock? Company insiders (like executives and directors) hold about 49.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 29.03%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.